SV

Street Verdict

Analyst Scorecard

CAPLIPOINT · NSE

Caplin Point Laboratories Limited

₹2,748.6

+5.85% (+₹152)

Prev. close

₹2,596.6

Volume

3,08,471

Delivery %

25.3%

As of

18 Sept 2026

Price history

₹2,748.6+₹439.2 (+19.02%) · 3M
10 Jun 2026 → 18 Sept 2026
₹2,845₹2,309.410 Jun03 Jul03 Aug26 Aug18 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on Caplin Point Laboratories Limited in the last 90 days.

Fundamentals

About Caplin Point Laboratories Limited

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Dr. Sridhar Ganesan

Headquarters

Chennai

Employees

4,199

Key stats

Market cap

₹20,892.58 Cr

P/E ratio (TTM)

31.5

Dividend yield

0.31%

EPS (TTM)

₹87.25

Beta (1Y · daily vs NIFTY 50)

0.97

Beta (5Y · monthly vs NIFTY 50)

1.06

Shares float

2.03 Cr

EPS · quarter ended Jun 2026

₹23.21

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr₹0%10%20%30%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

FY21 growth needs FY20 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

0255075100₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

01234₹-500%0%500%1000%12 Mar 2021 Sept 2018 May 2120 Sept 2123 May 2221 Sept 2209 Jun 2314 Sept 2331 May 2423 Sept 2430 May 2512 Sept 2529 May 2618 Sept 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr2000 Cr4000 Cr6000 Cr₹0×0.25×0.5×0.75×1×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr2000 Cr4000 Cr6000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

0 Cr250 Cr500 Cr750 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,061.29 Cr₹1,269.41 Cr₹1,466.73 Cr₹1,694.10 Cr₹1,937.47 Cr₹2,187.19 Cr
EBITDA₹352.18 Cr₹433.42 Cr₹497.12 Cr₹618.65 Cr₹743.36 Cr₹876.43 Cr
₹242.28 Cr₹300.00 Cr₹376.26 Cr₹457.08 Cr₹536.31 Cr₹641.24 Cr
Diluted EPS₹31.71₹39.26₹49.18₹59.9₹70.25₹84.11

Net income for Mar 2021 could not be independently verified against the company's own annual report: this page shows ₹242.28 Cr while the annual report gives ₹251.44 Cr (3.8% apart). That disagreement leaves the whole cross-check inconclusive, so Net income for Mar 2020 (the annual report alone gives ₹215.08 Cr) is left blank here too, rather than shown from only one of the two sources.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,364.00 Cr₹1,736.00 Cr₹2,191.00 Cr₹2,698.00 Cr₹3,208.00 Cr₹4,038.00 Cr
₹18.39 Cr₹2.13 Cr₹5.48 Cr₹1.97 Cr₹5.02 Cr₹4.61 Cr
Stockholders' equity₹1,185.83 Cr₹1,483.93 Cr₹1,880.48 Cr₹2,315.70 Cr₹2,850.49 Cr₹3,586.42 Cr

Trade receivables, Cash & equivalents, Long-term debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹269.00 Cr₹337.00 Cr₹271.00 Cr₹318.00 Cr₹432.00 Cr₹523.00 Cr
Investing cash flow₹-8.21 Cr₹-270.94 Cr₹-217.86 Cr₹-320.04 Cr₹-334.73 Cr₹-582.29 Cr
₹-24.00 Cr₹-41.00 Cr₹-28.00 Cr₹-38.00 Cr₹-38.00 Cr₹-46.00 Cr
Capital expenditure₹0₹-167.71 Cr₹-193.75 Cr₹-145.81 Cr₹-191.52 Cr₹-248.13 Cr
End cash position——₹177.56 Cr₹138.70 Cr₹199.45 Cr₹94.18 Cr

End cash position has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22Jun 22–Sep 22(2Q)Dec 22Mar 23Jun 23–Sep 23(2Q)Dec 23–Mar 24(2Q)Jun 24–Jun 25(5Q)Sep 25–Jun 26(4Q)
Promoter69.03%68.91%68.89%68.88%68.80%70.66%70.63%70.62%70.56%70.57%
Public30.97%31.09%31.11%31.12%31.20%29.34%29.37%29.38%29.44%29.43%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%—
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%—
Caplin Point Laboratories Limited₹19,633.82 Cr₹2,596.629.65.4717.9%0.00+13.0%+11.4%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Annual reports

Show all 29

Concall transcripts

Show all 11

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

23 indices

Nifty Smallcap250 Momentum Quality 100· 0.5%Nifty500 Healthcare· 0.4%Nifty500 Multicap Momentum Quality 50· 0.3%Nifty Total Market Momentum Quality 50· 0.3%BSE Healthcare· 0.3%BSE 250 SmallCap Index· 0.3%Nifty MidSmallcap400 Momentum Quality 100· 0.2%Nifty Smallcap 500· 0.2%Nifty MidSmallcap 400· 0.1%Nifty MidSmallcap400 50:50· 0.1%BSE 400 MidSmallCap Index· 0.1%BSE 1000· 0.0%

NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.

CAPLIPOINT

Caplin Point Laboratories Share Price rises 5.18% today

Univest · 1 day ago

CAPLIPOINT

Be Sure To Check Out Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Before It Goes Ex-Dividend

simplywall.st · 5 days ago